Trxade, Inc (MEDS) Corporate Media Kit

20 NASDAQ: MEDS • Reconciliation of Net Income to Adj. EBITDA *EBITDA and Adjusted EBITDA are non-GAAP financial measures. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. See also “Use of Non-GAAP Financial Information”, above. For the three months ended June 30, For the six months ended June 30, 2020 2019 2020 2019 Net Income attributable to Trxade Group, Inc. $ (542,587) $ 57,981 $ (362,284) $ 183,210 Add (deduct): Interest, net 7,310 15,874 15,234 33,432 Depreciation and amortization 1,250 1,250 2,500 2,500 EBITDA (534,027) 75,105 (344,550) 219,142 Add (deduct): Share in Equity losses on Investment - 58,850 - 87,822 Stock-based compensation 1,035,373 64,011 1,176,153 99,990 Adjusted EBITDA * $ 501,346 $ 197,966 $ 831,603 $ 406,954